With the height of the pandemic behind us, the future state of health care dynamics is starting to take shape. It is a future characterized by new relationships, incentives and needs between health systems, physicians, health plans and manufacturers. New dynamics catalyzed by:

• Investments by private equity and other corporate stakeholders to amass physician, ambulatory and technological assets to deliver care in ways that do not revolve around the hospital setting.
• Technological and practice innovations such as telehealth, remote patient monitoring (RPM) and home health enabling the delivery of ‘everywhere care’ for patients across all levels of complexity.
• A growing realization that drug spending is poised to equal procedural spending in terms of its importance to health systems finances and strategy.
• Increasing levels of proactivity from employers as they look to retain and attract talent in a tight labor environment while bending the cost curve. A change in federal legislation in 2021 also makes employers fiduciarily responsible for health care spend.

This year will prove pivotal in the long-term success of pharma and biotech companies as you develop organization-wide strategies inclusive of real-world data (RWD) for the next 12 to 18 months. That’s why life sciences market experts from Optum^® and Advisory Board came together once again to offer our take on 6 trends shaping pharmaceutical manufacturer strategies in 2024.

This analysis is rooted in conversations with more than 100 data scientists, researchers, clinicians, chief medical officers, medical directors, service line leaders and decision-makers across the health care landscape. The insights and recommendations captured here are intended to provoke thought, challenge conventional wisdom and stimulate cross-functional conversations that can accelerate meaningful industry change.